This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth
by Zacks Equity Research
Puma Biotech (PBYI) focuses on improving sales of its only marketed drug Nerlynx, which is approved for treating breast cancer. The drug's label expansion programs also look promising.
Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.
Blueprint Medicines Initiates Dosing in Liver Cancer Study
by Zacks Equity Research
Blueprint Medicines (BPMC) and partner CStone begin dosing in the phase Ib/II study on fisogatinib and CS1001 combo for treating patients with locally advanced/metastatic hepatocellular carcinoma.
Why Is Puma Biotech (PBYI) Down 1% Since Last Earnings Report?
by Zacks Equity Research
Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Puma Biotech Expands Pierre Fabre License to Add Countries
by Zacks Equity Research
Puma Biotech (PBYI) stretches its license deal with Pierre Fabre, granting the latter commercial rights to Nerlynx in new countries across Europe and parts of Africa. Stock rallies.
Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.
Puma (PBYI) Q3 Earnings Beat, Nerlynx Sales Weak, Stock Down
by Zacks Equity Research
Puma Biotech (PBYI) incurs narrower loss in Q3. Sales of Nerlynx decline sequentially. Stock drops 18%.
Puma Biotech (PBYI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 42.11% and -7.43%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Puma Biotech (PBYI) Q3 Earnings Expected to Decline
by Zacks Equity Research
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Puma Biotech Gets FDA Nod of Labeling Supplement for Nerlynx
by Zacks Equity Research
The FDA approves the label update of Puma Biotech's (PBYI) breast cancer drug Nerlynx in order to add data from the CONTROL study. Stock gains.
Do Options Traders Know Something About Puma Biotech (PBYI) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Puma Biotech (PBYI) stock based on the movements in the options market lately.
Roche's New Perjeta Combo Meets Goal in Breast Cancer Study
by Zacks Equity Research
Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.
Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts for review Puma Biotech's (PBYI) sNDA that seeks an approval for Nerlynx in combination with Roche's Xeloda for treating third-line breast cancer.
Why Is Puma Biotech (PBYI) Up 16.8% Since Last Earnings Report?
by Zacks Equity Research
Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Puma (PBYI) Q2 Earnings Miss, Nerlynx Sales Rise, Stock Up
by Zacks Equity Research
Puma Biotech (PBYI) incurs wider loss in Q2. Sales of Nerlynx improve from first-quarter levels. Stock rises 23%.
ArQule (ARQL) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On ArQule's (ARQL) second-quarter earnings call, investor focus will be on the company's early-stage pipeline candidates, which are under development for treating several cancers and rare diseases.
Puma Biotech (PBYI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Puma Biotech (PBYI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Puma Biotech (PBYI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Puma Biotech (PBYI) stock based on the movements in the options market lately.
Puma Biotech Submits sNDA for Breast Cancer Drug Nerlynx
by Zacks Equity Research
Puma Biotech (PBYI) files an sNDA for the nod of Nerlynx in combination with Xeloda to treat patients with HER2-positive metastatic breast cancer, having failed two or more prior lines of treatments.
Puma Biotech (PBYI) Down 53.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Puma Biotech (PBYI) Q1 Earnings Top, Nerlynx Disappoints
by Zacks Equity Research
Puma Biotech (PBYI) incurs narrower loss in Q1. Sales of Nerlynx fall short of expectations due to higher discontinuations. Stock plunges 32.5%.
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 62.32% and 53.64%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Puma Biotech (PBYI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Puma Biotech Adds Two Cohorts to Nerlynx Label Expansion Study
by Zacks Equity Research
Puma Biotech (PBYI) increases cohorts in the phase II SUMMIT basket study on Nerlynx for cancer patients suffering tumors with activating EGFR or HER2 mutations.
Puma Biotech Out-Licenses Nerlynx Rights in Europe, Stock Down
by Zacks Equity Research
Puma Biotech (PBYI) out-licenses development and marketing rights to its breast cancer drug Nerlynx to Pierre Fabre in Europe and across some African countries. Shares fall.